

# CITATION REPORT

List of articles citing

**Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine**

**DOI: 10.1016/s0009-9236(97)90027-8**

**Clinical Pharmacology and Therapeutics, 1997, 62, 248-60.**

**Source:** <https://exaly.com/paper-pdf/28826383/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
628	Influence of race or ethnicity on pharmacokinetics of drugs. <b>1997</b> , 86, 1328-33		93
627	Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. <b>1997</b> , 27, 201-214		231
626	Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. <b>1997</b> , 25, 647-72		13
625	Jejunal absorption and metabolism of R/S-verapamil in humans. <b>1998</b> , 15, 856-62		81
624	Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. <b>1998</b> , 15, 1609-13		62
623	Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. <b>1998</b> , 87, 1322-30		340
622	Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. <b>1998</b> , 358, 289-94		110
621	Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. <b>1998</b> , 62, PL135-42		67
620	Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival. <b>1998</b> , 30, 1980-2		3
619	The pharmacological role of P-glycoprotein in the intestinal epithelium. <b>1998</b> , 37, 429-35		104
618	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. <b>1998</b> , 350, 340-7		81
617	Metabolism of fibric acid derivatives. <b>1998</b> , 34, 419-20		6
616	Modulation by dietary salt of verapamil disposition in humans. <b>1998</b> , 98, 2702-8		28
615	Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?. <b>1998</b> , 38, 959-65		52
614	Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. <b>1999</b> , 48, 543-52		132
613	The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. <b>1999</b> , 48, 180-9		59
612	The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. <b>1999</b> , 29 Suppl 3, 116-24		52

611	The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. <b>1999</b> , 13, 494-500		83
610	The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 454-60	6.1	35
609	Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 461-71	6.1	212
608	In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 40-50	6.1	29
607	6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 65, 237-44	6.1	162
606	Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. <b>1999</b> , 16, 625-32		52
605	Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach. <b>1999</b> , 16, 225-31		100
604	CYP2E1-dependent benzene toxicity: the role of extrahepatic benzene metabolism. <b>1999</b> , 73, 189-96		30
603	A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. <b>1999</b> , 19, 753-9		13
602	Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. <b>1999</b> , 62, 25-31		250
601	Oral absorption of the HIV protease inhibitors: a current update. <b>1999</b> , 39, 211-238		114
600	Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. <b>1999</b> , 57, 1227-32		27
599	Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. <b>1999</b> , 13, 219-22		27
598	Cyclosporin pharmacokinetics in the elderly. <b>1999</b> , 15, 197-205		39
597	Metabolism-based drug interactions involving oral azole antifungals in humans. <i>Drug Metabolism Reviews</i> , <b>1999</b> , 31, 665-717	7	23
596	Advances in small-bowel transplantation. <b>1999</b> , 13, 203-217		3
595	Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. <b>1999</b> , 18, 150-9		50
594	Generic immunosuppressants: the European perspective. <b>1999</b> , 31, 19S-22S		3

593	Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets. <b>1999</b> , 31, 25S-30S	7
592	Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. <b>1999</b> , 117, 89-98	123
591	Cytochrome P450 3A: ontogeny and drug disposition. <b>1999</b> , 37, 485-505	413
590	Possible interaction between clindamycin and cyclosporin. <b>1999</b> , 319, 163	8
589	P-glycoprotein and drug therapy in organ transplantation. <b>1999</b> , 39, 995-1005	92
588	An individual bioequivalence approach to compare the intrasubject variability of two ciclosporin formulations, SangCya and Neoral. <b>1999</b> , 59, 78-88	6
587	Use of allochimeric proteins to mitigate graft-versus-host and host-versus-graft immune responses to rat small bowel allografts. <b>2000</b> , 70, 1060-7	
586	Therapeutic drug monitoring in solid-organ transplant recipients. <b>2000</b> , 5, 330-335	3
585	Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. <b>2000</b> , 22, 181-94	13
584	Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. <b>2000</b> , 89, 967-78	159
583	Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. <b>2000</b> , 26, 545-51	27
582	Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. <b>2000</b> , 130, 1369-77	109
581	Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. <b>2000</b> , 14, 519-25	21
580	Can oral midazolam predict oral cyclosporine disposition?. <b>2000</b> , 12, 51-62	15
579	Modulation of oral bioavailability of anticancer drugs: from mouse to man. <b>2000</b> , 12, 103-10	112
578	Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. <b>2000</b> , 12, 3-12	254
577	Variability in activity of hepatic CYP3A4 in patients infected with HIV. <b>2000</b> , 20, 898-907	34
576	Virtual screening of intestinal drug permeability. <b>2000</b> , 65, 231-43	88

575	Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. <b>2000</b> , 17, 291-8		35
574	Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. <b>2000</b> , 17, 1189-97		67
573	Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 67, 242-8	6.1	22
572	Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 98-103	6.1	88
571	Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 478-86	6.1	58
570	St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 598-604	6.1	413
569	Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. <b>2000</b> , 150, 185-90		31
568	Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. <b>2000</b> , 56, 693-8		57
567	Discrimination of Prohibited Oral Use of Salbutamol from Authorized Inhaled Asthma Treatment. <b>2000</b> , 46, 1365-1375		57
566	Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. <b>2000</b> , 59, 146-8		10
565	P-glycoprotein and bioavailability-implication of polymorphism. <b>2000</b> , 38, 877-81		18
564	Drug interaction between St. John's wort and cyclosporine. <b>2000</b> , 34, 1013-6		172
563	The effect of rifampin treatment on intestinal expression of human MRP transporters. <b>2000</b> , 157, 1575-80		249
562	Altered development of intestinal intraepithelial lymphocytes in P-glycoprotein-deficient mice. <b>2000</b> , 24, 783-95		34
561	Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. <b>2000</b> , 22 Suppl B, B1-13		15
560	Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. <b>2000</b> , 22 Suppl B, B101-121		205
559	Drug-grapefruit juice interactions. <b>2000</b> , 75, 933-42		223
558	Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. <b>2000</b> , 14, 355-69		15

557	Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. <b>2000</b> , 17, 599-614	43
556	HMG-CoA reductase inhibitors and myotoxicity. <b>2000</b> , 22, 441-57	203
555	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. <b>2000</b> , 38, 111-80	396
554	Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. <b>2001</b> , 2, 401-15	54
553	Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. <b>2001</b> , 11, 275-83	100
552	The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. <b>2001</b> , 40, 159-68	398
551	Clinical pharmacokinetics of sirolimus. <b>2001</b> , 40, 573-85	223
550	Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. <b>2001</b> , 40, 833-68	96
549	Role of P-Glycoprotein and Organic Anion Transporting Polypeptides in Drug Absorption and Distribution. <b>2001</b> , 21, 587-596	13
548	P-glycoprotein interactions of nefazodone and trazodone in cell culture. <b>2001</b> , 41, 708-14	34
547	Property-based design: optimization of drug absorption and pharmacokinetics. <b>2001</b> , 44, 1313-33	530
546	P-glycoprotein in the catfish intestine: inducibility by xenobiotics and functional properties. <b>2001</b> , 55, 157-70	44
545	Molecular basis of ethnic differences in drug disposition and response. <b>2001</b> , 41, 815-50	471
544	Drug interactions/P450. <b>2001</b> , 13, 141-152	3
543	Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. <b>2001</b> , 20, 431-8	19
542	Choosing the right dose of new immunosuppressive drugs for new populations: importance of pharmacokinetic studies. <b>2001</b> , 33, 1095-6	9
541	Immunosuppressive drugs in paediatric liver transplantation. <b>2001</b> , 3, 43-60	18
540	Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter?. <b>2001</b> , 41, 317-23	43

539	No Influence of the MDR-1 C3435T Polymorphism or a CYP3A4 Promoter Polymorphism (CYP3A4-V Allele) on Dose-adjusted Cyclosporin A Trough Concentrations or Rejection Incidence in Stable Renal Transplant Recipients. <b>2001</b> , 47, 1048-1052		249
538	The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. <b>2001</b> , 71, 1303-7		71
537	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. <b>2001</b> , 11, 555-72		269
536	Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. <b>2001</b> , 71, 1069-75		16
535	Herb-drug interactions: focus on pharmacokinetics. <b>2001</b> , 6, 827-32		17
534	Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat. <b>2001</b> , 71, 1585-92		13
533	Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. <b>2001</b> , 62, 1046-50		22
532	The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. <b>2001</b> , 11, 293-8		341
531	Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. <b>2001</b> , 57, 305-7		15
530	Identification of an organic anion transport system in the human colon carcinoma cell line HT29 clone 19A. <b>2001</b> , 441, 529-37		26
529	Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. <b>2001</b> , 15, 95-9		35
528	Tacrolimus and diarrhea: pathogenesis of altered metabolism. <b>2001</b> , 5, 75-9		33
527	Effect of grapefruit juice on digoxin pharmacokinetics in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 317-326	6.1	125
526	Red wine decreases cyclosporine bioavailability. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 468-474		34
525	Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. <b>2001</b> , 44, 2027-34		58
524	Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. <b>2001</b> , 18, 432-8		61
523	Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. <b>2001</b> , 18, 1721-8		14
522	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 69, 169-74	6.1	541

521	Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 69, 32-40	6.1	48
520	Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 69, 308-16	6.1	90
519	HMG-CoA reductase inhibitors and P-glycoprotein modulation. <b>2001</b> , 132, 1183-92		141
518	Predicting the impact of physiological and biochemical processes on oral drug bioavailability. <b>2001</b> , 50 Suppl 1, S41-67		472
517	Drug-nutrient interactions in transplant recipients. <b>2001</b> , 25, 132-41		15
516	Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. <b>2001</b> , 59, 974-80		128
515	Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. <b>2001</b> , 276, 14581-7		643
514	Preprescription genotyping: not yet ready for prime time, but getting there. <b>2001</b> , 103, 1608-10		22
513	The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. <b>2001</b> , 6, 95-109		3
512	Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection. <b>2001</b> , 22, 559-80		10
511	Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. <b>2002</b> , 30, 763-70		97
510	Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. <b>2002</b> , 301, 174-86		42
509	Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. <b>2002</b> , 300, 1036-45		264
508	Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. <b>2002</b> , 24, 47-52		24
507	Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?. <b>2002</b> , 24, 40-6		73
506	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. <b>2002</b> , 12, 451-7		175
505	Review: metabolism of immunosuppressant drugs. <i>Current Drug Metabolism</i> , <b>2002</b> , 3, 275-87	3.5	81
504	Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. <b>2002</b> , 25, 1356-9		117



503	C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. <b>2002</b> , 24, 400-4		79
502	Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. <b>2002</b> , 302, 645-50		357
501	The Pharmacogenomics of Human P-Glycoprotein. 159-178		4
500	Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 1-9	6.1	187
499	The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?. <b>2002</b> , 41, 235-53		172
498	How important are gender differences in pharmacokinetics?. <b>2002</b> , 41, 329-42		297
497	Mechanisms of clinically relevant drug interactions associated with tacrolimus. <b>2002</b> , 41, 813-51		217
496	Mammalian ABC transporters in health and disease. <b>2002</b> , 71, 537-92		1285
495	Pharmacokinetic differences between ethnic groups. <b>2002</b> , 359, 78-79		1
494	The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. <b>2002</b> , 71, 1149-60		78
493	Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. <b>2002</b> , 4, E29		16
492	Drug interactions: Proteins, pumps, and P-450s. <b>2002</b> , 47, 467-84; quiz 485-8		74
491	Genetic defects in hepatobiliary transport. <b>2002</b> , 1586, 129-45		92
490	Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient. <b>2002</b> , 22, 387-90		10
489	The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. <b>2002</b> , 54, 1295-310		206
488	ACE genotype and ACE inhibitor response in kidney disease: a perspective. <b>2002</b> , 40, 227-35		29
487	Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. <b>2002</b> , 91, 77-90		42
486	Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. <b>2002</b> , 91, 719-29		104

485	The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. <b>2002</b> , 16, 262-72		33
484	Interaction of chloramphenicol and the calcineurin inhibitors in renal transplant recipients. <b>2002</b> , 4, 169-74		6
483	Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. <b>2002</b> , 90, 5-13		48
482	MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. <b>2002</b> , 53, 526-34		201
481	St John's wort ( <i>Hypericum perforatum</i> ): drug interactions and clinical outcomes. <b>2002</b> , 54, 349-56		237
480	Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. <b>2002</b> , 245, 143-51		32
479	Genetically determined differences in P-glycoprotein function: implications for disease risk. <b>2002</b> , 181-182, 299-303		40
478	Multidrug resistance in cancer: role of ATP-dependent transporters. <b>2002</b> , 2, 48-58		4255
477	Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. <b>2002</b> , 58, 515-20		45
476	Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats. <b>2002</b> , 19, 1362-7		3
475	Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 474-89	6.1	116
474	Understanding and controlling hepatobiliary function. <b>2002</b> , 16, 1025-34		9
473	Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 131-40	6.1	32
472	CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 280-5	6.1	11
471	Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 297-303	6.1	205
470	Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 209-19	6.1	264
469	The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 572-83	6.1	161
468	Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 524-35	6.1	37

467	Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 660-9	6.1	110
466	Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. <b>2003</b> , 20, 757-64		53
465	Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine. <b>2003</b> , 20, 765-71		16
464	Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. <b>2003</b> , 20, 1163-9		62
463	P-glycoprotein increases from proximal to distal regions of human small intestine. <b>2003</b> , 20, 1595-9		220
462	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 74, 245-54	6.1	501
461	Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. <b>2003</b> , 9, 130-7		56
460	Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. <b>2003</b> , 9, 1108-13		23
459	Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 41-50	6.1	184
458	P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 223-31	6.1	119
457	Hepatic drug metabolism and transport in patients with kidney disease. <b>2003</b> , 42, 906-25		89
456	Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. <b>2003</b> , 20, 324-7		22
455	Genetic polymorphisms of the human MDR1 drug transporter. <b>2003</b> , 43, 285-307		265
454	Arzneimitteltransporter. <b>2003</b> , 44, 219-226		1
453	Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. <b>2003</b> , 16, 494-503		2
452	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <b>2003</b> , 2, 347-56		321
451	Development, function and maintenance of T lymphocyte populations in P-glycoprotein-deficient mice. <b>2003</b> , 4, 49-58		
450	Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. <b>2003</b> , 65, 1843-52		111

449	Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. <b>2003</b> , 55, 53-81	256
448	Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. <b>2003</b> , 92, 604-10	27
447	Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and beta-methyldigoxin in rats. <b>2003</b> , 92, 1455-63	19
446	Morphology and function of canine small intestinal autografts: with particular interest in the influence of ex vivo graft irradiation. <b>2003</b> , 7, 662-71	1
445	Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. <b>2003</b> , 55, 203-11	122
444	Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. <b>2003</b> , 56, 78-83	87
443	The effects of fruit juices on drug disposition: a new model for drug interactions. <b>2003</b> , 33 Suppl 2, 10-6	89
442	Importance of P-glycoprotein for drug disposition in humans. <b>2003</b> , 33 Suppl 2, 6-9	108
441	Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. <b>2003</b> , 16, 494-503	16
440	Role of P-glycoprotein in pharmacokinetics: clinical implications. <b>2003</b> , 42, 59-98	593
439	Factors affecting the clinical development of cytochrome p450 3A substrates. <b>2003</b> , 42, 969-84	44
438	Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. <b>2003</b> , 42, 1161-78	31
437	Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption. <b>2003</b> , 23, 463-72	24
436	Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. <b>2003</b> , 152, 739-48	46
435	Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. <b>2003</b> , 35, 1295-7	8
434	The effects of thermal injury on transcellular permeability and intestinal P-glycoprotein in rats. <b>2003</b> , 29, 803-9	5
433	MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. <b>2003</b> , 73, 1282-92	187
432	Stereochemical Aspects of Drug Action and Disposition. <b>2003</b> ,	18

431	Drug interactions of clinical significance for the dermatologist: recognition and avoidance. <b>2003</b> , 4, 623-39	7
430	The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. <b>2003</b> , 3, 291-301	26
429	Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. <b>2003</b> , 31, 1214-26	30
428	ABC of oral bioavailability: transporters as gatekeepers in the gut. <b>2003</b> , 52, 1788-95	227
427	Predicting oral absorption and bioavailability. <b>2003</b> , 41, 1-59	26
426	The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients. <b>2003</b> , 43, 555-564	109
425	Cholestasis. <b>2003</b> , 52 Suppl 2, ii42-8	17
424	Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. <b>2003</b> , 31, 373-83	64
423	Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. <b>2003</b> , 76, 865-8	42
422	Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. <b>2003</b> , 13, 89-95	225
421	Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. <b>2003</b> , 25, 107-11	57
420	Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. <b>2003</b> , 25, 158-66	15
419	Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. <b>2003</b> , 25, 305-9	48
418	Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients. <b>2003</b> , 25, 665-70	20
417	Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. <b>2003</b> , 13, 661-74	74
416	Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. <b>2003</b> , 43, 1168-76	46
415	MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. <b>2003</b> , 43, 1101-7	55
414	The Importance of Gut Wall Metabolism in Determining Drug Bioavailability. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2003</b> , 311-328	0.4 6

413	Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. <b>2003</b> , 76, 358-63		9
412	In Vivo Permeability Studies in the Gastrointestinal Tract of Humans. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2003</b> , 155-188	0.4	5
411	[MDR1 genotypes related to pharmacokinetics and MDR1 expression]. <b>2003</b> , 123, 773-9		7
410	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. <b>2003</b> , 26, 510-7		56
409	The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. <b>2003</b> , 18, 365-72		69
408	Drug metabolism in chronic renal failure. <i>Current Drug Metabolism</i> , <b>2003</b> , 4, 91-103	3.5	96
407	[Elevated cyclosporine A trough levels in HCV positive kidney transplant recipients]. <b>2003</b> , 49, 141-4		1
406	Physiological Modeling of the Small Intestine in Drug Absorption. <b>2004</b> , 3-32		
405	Intestinal drug transporters: in vivo function and clinical importance. <i>Current Drug Metabolism</i> , <b>2004</b> , 5, 109-24	3.5	116
404	Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. <i>Current Drug Metabolism</i> , <b>2004</b> , 5, 375-88	3.5	80
403	Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. <b>2004</b> , 44, 1083-105		148
402	Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. <b>2004</b> , 310, 359-66		26
401	The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. <b>2004</b> , 309, 730-6		30
400	Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. <b>2004</b> , 14, 1333-44		94
399	Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. <b>2004</b> , 309, 720-9		48
398	Cellular Drug Delivery. <b>2004</b> ,		5
397	Effect of experimental acute renal and hepatic failure on absorption of tacrolimus in rat small intestine. <b>2004</b> , 19, 190-7		4
396	Cyclosporine pharmacokinetics in anti-HCV+ patients. <b>2004</b> , 18, 654-60		21

395	Therapeutic implications of the MDR-1 gene. <b>2004</b> , 27, 257-64		119
394	Functional interaction of intestinal CYP3A4 and P-glycoprotein. <b>2004</b> , 18, 621-6		89
393	Food-drug interaction: grapefruit juice augments drug bioavailability--mechanism, extent and relevance. <b>2004</b> , 58, 1-9		173
392	PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. <b>2004</b> , 199, 251-65		163
391	Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. <b>2004</b> , 2, 8		42
390	The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. <b>2004</b> , 21, 25-51		482
389	Evaluation of acetaminophen P-glycoprotein-mediated salivary secretion by rat submandibular glands. <b>2004</b> , 49, 895-901		7
388	Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. <b>2004</b> , 67, 285-92		34
387	In vitro metabolism of cyclosporine A by human kidney CYP3A5. <b>2004</b> , 68, 1889-902		103
386	Het juiste geneesmiddel voor de juiste patiënt: farmacogenetica in de kindergeneeskundige praktijk. <b>2004</b> , 72, 94-101		
385	Gene expression of cytochromes P450 in liver transplants over time. <b>2004</b> , 60, 413-20		10
384	Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. <b>2004</b> , 8, 151-60		29
383	Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. <b>2004</b> , 272, 161-71		48
382	Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 75, 172-83	6.1	200
381	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 75, 422-33	6.1	150
380	Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 330-40	6.1	97
379	A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 418-27	6.1	85
378	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 545-56	6.1	128

377	Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. <b>2004</b> , 1, 290-9		39
376	Pharmacokinetic interactions of drugs with St John's wort. <b>2004</b> , 18, 262-76		195
375	The MDR1 (ABCB1) gene polymorphism and its clinical implications. <b>2004</b> , 43, 553-76		113
374	Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. <b>2004</b> , 43, 623-53		562
373	Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. <b>2004</b> , 43, 741-62		92
372	Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques. <b>2004</b> , 1, 363-7		22
371	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. <b>2004</b> , 21, 553-60		62
370	Herbal modulation of P-glycoprotein. <i>Drug Metabolism Reviews</i> , <b>2004</b> , 36, 57-104	7	316
369	MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. <b>2004</b> , 78, 21-5		64
368	Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. <b>2004</b> , 78, 311-5		38
367	Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. <b>2004</b> , 11, 433-42		23
366	Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. <b>2004</b> , 26, 415-24		25
365	CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. <b>2004</b> , 26, 524-8		59
364	Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. <b>2004</b> , 26, 408-14		41
363	Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). <b>2004</b> , 14, 309-18		96
362	Biomarkers of immunosuppressive drug toxicity. <b>2005</b> , 10, 284-294		8
361	Mechanisms of Drug Interactions II. <b>2005</b> , 41-82		9
360	MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. <b>2005</b> , 27, 531-5		35



359	CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. <b>2005</b> , 15, 779-86		78
358	Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. <b>2005</b> , 27, 587-91		20
357	Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. <b>2005</b> , 45, 954-60		81
356	Efflux Transporters in Drug Excretion. <b>2005</b> , 381-410		2
355	Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A. <b>2005</b> , 28, 760-3		14
354	Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. <b>2005</b> , 303, 8-19		45
353	P-glycoprotein and surfactants: effect on intestinal talinolol absorption. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 24-32	6.1	80
352	Transporters and drug therapy: implications for drug disposition and disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 260-77	6.1	366
351	Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 605-18	6.1	77
350	AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. <b>2005</b> , 67, 2440-7		126
349	Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. <b>2005</b> , 59, 18-27		21
348	Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. <b>2005</b> , 60, 54-60		162
347	Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. <b>2005</b> , 30, 549-57		16
346	Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. <b>2005</b> , 70, 695-9		133
345	Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. <b>2005</b> , 5, 595-603		116
344	Pharmacokinetic principles of immunosuppressive drugs. <b>2005</b> , 5, 207-17		53
343	Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in <i>Zanthoxyli fructus</i> . <b>2005</b> , 209, 167-73		46
342	Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. <b>2005</b> , 25, 646-53		25

341	Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. <b>2005</b> , 56, 173-81	53
340	A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. <b>2005</b> , 50, 2312-5	19
339	The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. <b>2005</b> , 22, 1667-77	48
338	. <b>2005</b> ,	33
337	Pharmacokinetic principles and mechanisms of drug interactions. <b>2005</b> , 47-56	
336	Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. <b>2005</b> , 46, 655-62	41
335	Oxidative metabolism by P450 and function coupling to efflux systems: modulation of mycotoxin toxicity. <b>2005</b> , 22, 361-8	10
334	Functional interactions between P-glycoprotein and CYP3A in drug metabolism. <b>2005</b> , 1, 641-54	80
333	Chemopreventive effects of aloe against genotoxicity induced by benzo[a]pyrene. <b>2005</b> , 68, 1841-60	7
332	Cytochrome P450 3A polymorphisms and immunosuppressive drugs. <b>2005</b> , 6, 37-47	44
331	A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. <b>2005</b> , 386, 503-13	113
330	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. <b>2005</b> , 6, 323-37	76
329	Gender Differences in the Pharmacokinetics of Oral Dermatologic Medications. <b>2005</b> , 23, 119-133	4
328	Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?. <b>2005</b> , 39, 119-27	24
327	Limitations of C2 monitoring in renal transplant recipients. <b>2005</b> , 20, 1463-70	20
326	Drug dosing in chronic kidney disease. <b>2005</b> , 89, 649-87	60
325	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. <b>2005</b> , 6, 2593-605	6
324	Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. <b>2005</b> , 33, 219-24	138

323	The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients. <b>2005</b> , 24, 2144-7	15
322	The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. <b>2005</b> , 88, 715-38	57
321	Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. <b>2005</b> , 28, 677-94	72
320	The influence of age and sex on the clearance of cytochrome P450 3A substrates. <b>2005</b> , 44, 33-60	215
319	Sirolimus: the evidence for clinical pharmacokinetic monitoring. <b>2005</b> , 44, 769-86	84
318	Herb-drug interactions: a literature review. <b>2005</b> , 65, 1239-82	417
317	Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. <b>2005</b> , 23, 443-64	56
316	Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. <b>2005</b> , 22, 541-57	44
315	Transporters and their impact on drug disposition. <b>2005</b> , 39, 1097-108	45
314	Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. <b>2005</b> , 45, 411-21	14
313	Pharmacokinetics and Clinical Efficacy of Cyclosporine Treatment of Dogs with Steroid-Refractory Inflammatory Bowel Disease. <b>2006</b> , 20, 239-244	82
312	Clinical pharmacokinetics of voriconazole. <b>2006</b> , 27, 274-84	116
311	Effects of hepatic fibrosis on ofloxacin pharmacokinetics in rats. <b>2006</b> , 53, 28-34	21
310	P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites. <b>2006</b> , 45, 15505-19	24
309	Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. <b>2006</b> , 44, 1572-8	46
308	Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products. <b>2006</b> , 44, 2033-9	55
307	Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. <b>2006</b> , 60, 508-19	124
306	Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. <b>2006</b> , 28, 39-44	71

305	Determination of p-glycoprotein ATPase activity using luciferase. <b>2006</b> , 29, 560-4		11
304	Peripheral blood lymphocytes P-glycoprotein (P-gp, gp-170) expression in allogenic kidney transplant patients. <b>2006</b> , 11, 257-60		3
303	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. <b>2006</b> , 62, 485-91		20
302	Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 255-62	6.1	66
301	MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 325-38	6.1	84
300	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 331-45	6.1	79
299	Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. <b>2006</b> , 309, 81-6		12
298	Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. <b>2006</b> , 23, 1243-50		206
297	The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. <b>2006</b> , 256, 281-6		55
296	Prediction of systemic exposure to cyclosporine in Japanese pediatric patients. <b>2006</b> , 51, 969-976		8
295	Hyperforin in St. John's wort drug interactions. <b>2006</b> , 62, 225-33		133
294	Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. <b>2006</b> , 72, 1042-50		21
293	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. <b>2006</b> , 112, 184-98		151
292	Population pharmacokinetics of cyclosporine in chinese cardiac transplant recipients. <b>2006</b> , 26, 790-7		8
291	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing. <b>2006</b> , 12, 292-300		16
290	Effects of citronellal, a monoterpenoid in <i>Zanthoxyl Fructus</i> , on the intestinal absorption of digoxin in vitro and in vivo. <b>2006</b> , 95, 552-60		4
289	MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. <b>2006</b> , 95, 2293-308		113
288	Gender: a possible determinant in dosing of dermatologic drugs--an overview. <b>2006</b> , 25, 195-210		4

287	Rechtzeitig daran denken - Unerwünschte Arzneimittelwirkungen durch Interaktionen mit Antiinfektiva. <b>2006</b> , 35, 324-329		
286	Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. <b>2006</b> , 55, 395-402		55
285	A T3587G germ-line mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein. <b>2006</b> , 5, 877-84		13
284	Placental Transfer. <b>2006</b> , 2787-2846		14
283	Human pharmacogenomic variations and their implications for antifungal efficacy. <b>2006</b> , 19, 763-87		31
282	Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. <b>2006</b> , 73, 142-50		78
281	Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. <b>2006</b> , 46, 768-75		5
280	Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. <b>2006</b> , 23, 962-75		45
279	Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. <b>2006</b> , 3, 23-35		22
278	Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. <b>2006</b> , 34, 305-10		29
277	Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. <b>2007</b> , 35, 110-5		103
276	Prediction of intestinal first-pass drug metabolism. <i>Current Drug Metabolism</i> , <b>2007</b> , 8, 676-84	3.5	286
275	Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. <b>2007</b> , 35, 922-8		50
274	Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. <b>2007</b> , 35, 410-8		49
273	Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. <b>2007</b> , 34, 823-31		40
272	P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. <b>2007</b> , 31, 878-86		20
271	Advanced delivery of ciclosporin A: present state and perspective. <b>2007</b> , 4, 349-58		23
270	Diet/Nutrient Interactions with Drug Transporters. 665-708		2

269	Intestinal permeability and its relevance for absorption and elimination. <b>2007</b> , 37, 1015-51	211
268	The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. <b>2007</b> , 3, 315-20	19
267	Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. <b>2007</b> , 47, 566-78	283
266	Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery. <b>2007</b> , 157-215	17
265	Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. <b>2007</b> , 8, 835-49	77
264	Gut instincts: CYP3A4 and intestinal drug metabolism. <b>2007</b> , 117, 3173-6	74
263	Enaminones: Exploring additional therapeutic activities. <b>2007</b> , 96, 2509-31	70
262	Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies. <b>2007</b> , 332, 147-52	22
261	Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. <b>2007</b> , 336, 233-40	59
260	Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. <b>2007</b> , 852, 345-52	32
259	Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 539-46	6.1 102
258	Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. <b>2007</b> , 64, 772-84	42
257	A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies. <b>2007</b> , 30, 432-40	22
256	Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. <b>2007</b> , 63, 917-25	30
255	Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. <b>2008</b> , 29, 1-5	54
254	Explorations into modeling human oral bioavailability. <b>2008</b> , 43, 2442-52	17
253	Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics. <b>2008</b> , 158, 215-22	37
252	Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. <b>2008</b> , 103, 433-44	43

251	Effects of liver fibrosis on verapamil pharmacokinetics in rats. <b>2008</b> , 35, 287-94	9
250	ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. <b>2008</b> , 66, 240-6	18
249	Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. <b>2008</b> , 47, 383-97	30
248	Assessment of intestinal absorption of vitexin-2''-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models. <b>2008</b> , 34, 164-70	13
247	Handbook of Drug Monitoring Methods. <b>2008</b> ,	8
246	Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. <b>2008</b> , 78, 154-62	32
245	Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. <b>2008</b> , 40, 1690-5	42
244	PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. <b>2008</b> , 9, 1695-709	119
243	Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. <b>2008</b> , 327, 592-9	4
242	Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR112 and their association with CYP3A4 expression. <b>2008</b> , 36, 169-81	120
241	Drug-Drug Interactions, Second Edition. <b>2008</b> ,	6
240	Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. <b>2008</b> , 36, 1794-802	119
239	P-glycoprotein efflux transporter activity often displays biphasic dose-response relationships. <b>2008</b> , 38, 473-87	21
238	Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats. <b>2008</b> , 38, 147-55	12
237	In Vivo Permeability Studies in the Gastrointestinal Tract of Humans. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2008</b> , 185-219	0.4 1
236	Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. <b>2008</b> , 48, 1350-5	68
235	Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. <b>2008</b> , 49, 358-68	29
234	Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. <b>2008</b> , 23, 150-7	35

233	Intestinal metabolism and transport of drugs in children: the effects of age and disease. <b>2008</b> , 47, 3-10		60
232	Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. <i>Current Drug Metabolism</i> , <b>2008</b> , 9, 785-95	3.5	53
231	Molecular mechanisms underlying St. John's wort drug interactions. <i>Current Drug Metabolism</i> , <b>2008</b> , 9, 1027-37	3.5	50
230	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. <b>2008</b> , 18, 77-90		63
229	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. <b>2008</b> , 30, 689-99		57
228	Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. <b>2008</b> , 86, 1379-83		40
227	Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. <b>2008</b> , 85, 179-84		53
226	Introduction to Clinical Pharmacology. <b>2009</b> , 321-338		1
225	Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. <b>2009</b> , 37, 1604-10		46
224	Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. <b>2009</b> , 39, 931-8		19
223	A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. <b>2009</b> , 106, 5394-9		21
222	Drug monitoring in inflammatory bowel disease: helpful or dispensable?. <b>2009</b> , 27, 394-403		12
221	Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. <b>2009</b> , 133, 77-84		81
220	Safety testing of metabolites: Expectations and outcomes. <b>2009</b> , 179, 45-59		30
219	Cyclosporine Therapeutic Monitoring With CMAX in Kidney Transplant Recipients: Impact of Schistosomal Infection. <b>2009</b> , 38, 324-327		
218	Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. <b>2009</b> , 98, 327-36		4
217	Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa. <b>2009</b> , 98, 349-61		8
216	Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. <b>2009</b> , 98, 2180-97		39



215	Cyclosporine therapeutic monitoring with C(MAX) in kidney transplant recipients: racial considerations. <b>2009</b> , 13, 156-160		1
214	Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. <b>2009</b> , 65, 239-47		31
213	Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 605-8	6.1	13
212	Oral cyclosporine A--the current picture of its liposomal and other delivery systems. <b>2009</b> , 14, 139-52		52
211	The biological and clinical role of drug transporters at the intestinal barrier. <b>2009</b> , 35, 137-47		94
210	CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides. <b>2009</b> , 184, 159-68		36
209	Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. <b>2009</b> , 26, 715-37		58
208	Organic cation transporters and their roles in antiretroviral drug disposition. <b>2009</b> , 5, 773-87		9
207	Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. <b>2009</b> , 19, 77-85		28
206	Pharmacogenetics of calcineurin inhibitors in renal transplantation. <b>2009</b> , 88, S62-7		32
205	The Role of ABC Transporters at the Intestinal Barrier. 385-409		
204	Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives. <b>2010</b> , 16, 176-86		25
203	PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. <i>Current Drug Metabolism</i> , <b>2010</b> , 11, 743-61	3.5	47
202	Immunosuppressive Agents for the Prevention of Transplantation Rejection. <b>2010</b> , 983-1063		
201	Intestinal drug absorption and bioavailability: beyond involvement of single transport function. <b>2003</b> , 55, 429-33		21
200	Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. <b>2007</b> , 59, 1383-7		10
199	Cytochrome P450-mediated metabolism in the human gut wall. <b>2010</b> , 61, 541-558		180
198	Explaining variability in ciclosporin exposure in adult kidney transplant recipients. <b>2010</b> , 66, 579-90		27

197	Emerging new technologies in Pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1). <b>2010</b> , 126, 69-81	35
196	Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. <b>2010</b> , 183, 151-6	49
195	Interplay of transporters and enzymes in the Caco-2 cell monolayer: I. effect of altered apical secretion. <b>2010</b> , 31, 215-27	15
194	Grapefruit juice enhances the exposure to oral oxycodone. <b>2010</b> , 107, 782-8	39
193	Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs. <b>2010</b> , 33, 453-60	22
192	Membrane transporters in drug development. <b>2010</b> , 9, 215-36	2464
191	Coexistence of passive and carrier-mediated processes in drug transport. <b>2010</b> , 9, 597-614	428
190	P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions. <b>2010</b> , 25, 3-16	16
189	Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats. <b>2010</b> , 12, 512-4	11
188	Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. <b>2010</b> , 62, 1159-69	37
187	Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. <b>2010</b> , 596, 199-222	57
186	Introduction. <b>2010</b> , 1-28	
185	Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. <b>2010</b> , 49, 223-37	58
184	Pharmacogenetic Analysis of Calcineurin Inhibitors in Renal Transplant Patients: Towards Personalized Immunosuppressive Therapy?. <b>2010</b> , 4, 5-14	
183	Pharmacokinetic Principles. <b>2010</b> , 13-52	2
182	Pharmacology & Pharmacokinetics. <b>2010</b> ,	3
181	Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. <b>2011</b> , 63, 815-25	20
180	Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, and Humans. <b>2011</b> , 253-265	4

179	The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. <b>2011</b> , 7, 341-52	11
178	Drug Transporters. <b>2011</b> ,	13
177	Functional analysis of genetic variations in the 5'-flanking region of the human MDR1 gene. <b>2011</b> , 102, 91-8	13
176	The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. <b>1998</b> , 50, 729-35	42
175	Different transport activity of human triallelic MDR1 893Ala/Ser/Thr variant and its association with herb extracts. <b>2011</b> , 25, 1141-7	5
174	Pharmacogenetics and Renal Transplantation. <b>2011</b> ,	
173	Medical Attributes of St. John's Wort ( <i>Hypericum perforatum</i> ). <b>2011</b> , 211-237	22
172	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. <b>2011</b> , 52, 1894-904	68
171	In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. <b>2011</b> , 403-47	23
170	ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. <b>2011</b> , 12, 600-20	123
169	The effect of grapefruit juice on drug disposition. <b>2011</b> , 7, 267-86	137
168	The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. <b>2012</b> , 2012, 671702	16
167	QSPR in oral bioavailability: specificity or integrality?. <b>2012</b> , 12, 534-50	12
166	Donor ABCB1 variant associates with increased risk for kidney allograft failure. <b>2012</b> , 23, 1891-9	58
165	ADME of Herbal Dietary Supplements. <b>2012</b> , 1	1
164	Transporting Systems. <b>2012</b> , 199-222	
163	Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!. <b>2012</b> , 29, 2345-53	3
162	Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation. <b>2012</b> , 78, 412-8	10

161	Pharmacogenomics of Inflammatory Bowel Diseases. <b>2012</b> , 323-351		
160	Change of Cyclosporine Absorption over the Time after Kidney Transplantation. <b>2012</b> , 4, 470-4		5
159	P-glycoprotein expression in Helicobacter pylori-positive patients: the influence of MDR1 C3435T polymorphism. <b>2012</b> , 13, 414-20		8
158	Pharmacokinetics for the prescriber. <b>2012</b> , 40, 357-361		
157	Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients. <b>2013</b> , 2, 5		7
156	Utilisation de la ciclosporine en dermatologie fine: donnés actuelles. <b>2013</b> , 48, 33-40		
155	P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. <b>2013</b> , 273, 561-8		26
154	Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. <b>2013</b> , 76, 445-54		13
153	African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help?. <b>2013</b> , 45, 3498-501		14
152	From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. <b>2013</b> , 452, 14-35		48
151	Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. <b>2013</b> , 26, 177-86		27
150	Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study. <b>2013</b> , 102, 3196-204		11
149	Animal models of toxicology testing: the role of pigs. <b>2013</b> , 9, 127-39		80
148	Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 275-82	6.1	62
147	Potential risk of mulberry-drug interaction: modulation on P-glycoprotein and cytochrome P450 3A. <b>2013</b> , 61, 4464-9		18
146	PharmGKB summary: cyclosporine and tacrolimus pathways. <b>2013</b> , 23, 563-85		137
145	Rapid Quantitation of Furanocoumarins and Flavonoids in Grapefruit Juice using Ultra-Performance Liquid Chromatography. <b>2013</b> , 24, 654-60		19
144	Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. <b>2013</b> , 53, 1039-47		19

143	Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. <b>2013</b> , 53, 827-33		7
142	Functional alterations of intestinal P-glycoprotein under diabetic conditions. <b>2013</b> , 36, 1381-90		20
141	Radixin influences the changes in the small intestinal P-glycoprotein by etoposide treatment. <b>2013</b> , 36, 1822-8		16
140	Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2013</b> , 2, e47	4.5	16
139	Why We Need Proper PBPK Models to Examine Intestine and Liver Oral Drug Absorption. <i>Current Drug Metabolism</i> , <b>2013</b> , 14, 57-79	3.5	30
138	. <b>2014</b> ,		8
137	Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2014</b> , 3, e100	4.5	55
136	Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. <b>2014</b> , 40, 1616-22		16
135	Diet/Nutrient Interactions with Drug Transporters. <b>2014</b> , 409-432		2
134	Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. <b>2014</b> , 36, 46-53		7
133	Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions. <b>2014</b> , 210, 242-9		10
132	The pharmacology of novel oral anticoagulants. <b>2014</b> , 37, 217-33		45
131	Medaka villin 1-like protein (VILL) is associated with the formation of microvilli induced by decreasing salinities in the absorptive ionocytes. <b>2014</b> , 11, 2		4
130	Oral cyclosporine treatment in dogs: a review of the literature. <b>2014</b> , 28, 1-20		54
129	Interplay of drug metabolizing enzymes with cellular transporters. <b>2014</b> , 164, 461-71		3
128	Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions. <b>2014</b> , 10, 859-71		46
127	Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. <b>2014</b> , 21, 1115-42		336
126	Multidrug-resistance 1 gene single-nucleotide polymorphisms do not influence long-term graft survival after kidney transplantation. <b>2014</b> , 46, 2214-9		2

125	Relationship between permeability glycoprotein (P-gp) gene expression and enrofloxacin metabolism in Nile Tilapia. <b>2014</b> , 26, 59-65	4
124	Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations. <b>2014</b> , 124, 180-91	24
123	[Effect of repeated oral treatment with etoposide on the expression of intestinal P-glycoprotein and oral morphine analgesia]. <b>2014</b> , 134, 689-99	4
122	Kinetics of In Vitro Metabolism: Assimilation of Intrinsic Clearance in Hepatic Clearance. <b>2015</b> , 212-237	
121	Population Pharmacokinetic Approach to the Use of Low Dose Cyclosporine in Patients with Connective Tissue Diseases. <b>2015</b> , 38, 1265-71	2
120	[Role of Scaffold Proteins in Functional Alteration of Small Intestinal P-glycoprotein by Anti-cancer Drugs]. <b>2015</b> , 135, 687-95	2
119	Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. <b>2015</b> , 36, 575-86	13
118	Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. <b>2015</b> , 20, 424-30	15
117	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. <b>2015</b> , 71, 773-99	11
116	Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. <b>2015</b> , 29, 224-30	17
115	Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles. <b>2015</b> , 50, 508-19	32
114	Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation. <b>2015</b> , 36, 855-62	3
113	Interethnic differences in pharmacokinetics of antibacterials. <b>2015</b> , 54, 243-60	16
112	Preclinical Drug Development. <b>2016</b> ,	
111	Sex and Gender; Pharmacology, Efficacy, Toxicity, and Toxicology. 63-76	0
110	Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study. <b>2016</b> , 31, 161-7	15
109	Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic. <b>2016</b> ,	
108	Interactions between Nutraceuticals/Nutrients and Therapeutic Drugs. <b>2016</b> , 855-874	6

107	Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg. <b>2016</b> , 105, 431-442	6
106	Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo. <b>2016</b> , 5, 380	9
105	Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. <b>2016</b> , 96, 432-45	36
104	Age-mediated changes in the gastrointestinal tract. <b>2016</b> , 512, 382-395	53
103	Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. <b>2016</b> , 8, 333ra49	71
102	Hepatic, gastric and intestinal first-pass effects of vitexin-2''-O-rhamnoside in rats by ultra-high-performance liquid chromatography. <b>2016</b> , 30, 111-6	6
101	Interaction of Citrus Juices with Cyclosporine: Systematic Review and Meta-Analysis. <b>2016</b> , 41, 665-673	14
100	Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. <b>2016</b> , 12, 555-65	86
99	GIT Anatomy and Physiology and Drug Oral Bioavailability: Impact of Species Differences. <b>2017</b> , 35-76	1
98	Orally Absorbed Cyclic Peptides. <b>2017</b> , 117, 8094-8128	209
97	Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions. <b>2017</b> , 77, 859-883	59
96	Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics. <b>2017</b> , 44, 291-303	3
95	Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. <b>2017</b> , 18, 1503-1513	15
94	Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. <b>2017</b> , 39, 589-595	6
93	The expression of VILL protein is hypoosmotic-dependent in the lamellar gill ionocytes of Otocephala teleost fish, Chanos chanos. <b>2017</b> , 203, 59-68	2
92	Drug Metabolism in the Liver. <b>2017</b> , 21, 1-20	220
91	Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer. <b>2017</b> , 150, 89-97	29
90	Introduction to Clinical Pharmacology. <b>2017</b> , 365-388	6

89	Immunosuppressive Drugs. <b>2017</b> , 983-998.e4	2
88	Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models. <b>2017</b> , 9,	59
87	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. <b>2018</b> , 57, 1075-1106	10
86	Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. <b>2018</b> , 58, 979-989	7
85	Activation of P-glycoprotein and CYP 3A by Coptidis Rhizoma in vivo: Using cyclosporine as a probe substrate in rats. <b>2018</b> , 26, S125-S132	16
84	Personalized immunosuppression in elderly renal transplant recipients. <b>2018</b> , 130, 303-307	17
83	Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations. <b>2018</b> , 102, 107-114	19
82	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. <b>2018</b> , 40, 602-609	6
81	Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report. <b>2018</b> , 97, e12424	4
80	Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature. <b>2018</b> , 271-299	2
79	ADME Processes in Pharmaceutical Sciences. <b>2018</b> ,	6
78	Adverse effects of medicinal herbs on the human kidney. <b>2018</b> , 97, 51-58	
77	Gut Microbiota-Mediated Bile Acid Transformations Alter the Cellular Response to Multidrug Resistant Transporter Substrates in Vitro: Focus on P-glycoprotein. <b>2018</b> , 15, 5711-5727	8
76	PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2018</b> , 7, 647-659	4.5 61
75	Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier. <b>2018</b> , 43, 619-635	4
74	Geographic distribution of the 3435C>T polymorphism of the MDR1 gene in Peruvian populations. <b>2019</b> , 34,	0
73	Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats. <b>2019</b> , 71, 788-796	6
72	Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. <b>2019</b> , 566, 410-433	24



71	Genetic analysis of pharmacogenomic VIP variants in the Blang population from Yunnan Province of China. <b>2019</b> , 7, e574	4
70	Interaction of cyclosporine with phenobarbital in cats: a preliminary study. <b>2019</b> , 81, 1621-1623	1
69	St. John's Wort ( <i>Hypericum perforatum</i> ). <b>2019</b> , 415-432	0
68	Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling. <b>2020</b> , 10, 9717	
67	Excessive Cyclosporine-Associated Immunosuppression in a Dog Heterozygous for the MDR1 (ABCB1-1) Mutation. <b>2020</b> , 56, 190	2
66	Drug Interactions. <b>2021</b> , 725-742.e3	1
65	Drugs for the Skinternist. <b>2021</b> , 430-444.e3	
64	Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats. <b>2021</b> , 265, 113251	5
63	Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs. <b>2021</b> , 1175-1197	1
62	Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions. <b>2021</b> , 1297, 27-42	3
61	Immunosuppression Considerations for Older Kidney Transplant Recipients. <b>2021</b> , 8, 100-110	5
60	Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. <b>2021</b> , 12, 630904	3
59	Effects of Postoperative Day and NR112 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach. <b>2021</b> , 10, 1385-1394	0
58	ABCB1 in dermatology: roles in skin diseases and their treatment. <b>2021</b> , 99, 1527-1538	3
57	Recent progress in inflammatory bowel disease genetics. <b>2006</b> , 579, 24-34	1
56	Role of Mechanistic Transport Studies in Lead Optimization. <b>2006</b> , 25-47	3
55	ABC Transporter Proteins and Cellular Drug Resistance. <b>2004</b> , 129-162	2
54	Immunosuppressive Drugs. <b>2008</b> , 165-199	3

53	Stereoselective Drug Metabolism and Drug Interactions. <b>2003</b> , 313-339	4
52	Immunosuppressive Drugs. <b>2013</b> , 941-956.e4	2
51	Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. <b>1999</b> , 21, 304-9	48
50	Recommendations for bioequivalence testing of cyclosporine generics revisited. <b>2000</b> , 22, 330-45	26
49	Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. <b>1999</b> , 67, 333-5	45
48	Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. <b>2000</b> , 69, 76-86	44
47	Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort ( <i>Hypericum perforatum</i> ). <b>2000</b> , 69, 2229-30	84
46	Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. <b>2002</b> , 73, 159-60	10
45	The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. <b>1999</b> , 104, 147-53	693
44	Lipid-Based Formulations for Oral Administration. <b>2001</b> ,	1
43	Nanomedicines in renal transplant rejection--focus on sirolimus. <b>2007</b> , 2, 25-32	39
42	Establishment of a P-glycoprotein substrate screening model and its preliminary application. <b>2004</b> , 10, 1365-8	16
41	Calcineurin inhibitor-induced renal allograft nephrotoxicity. <b>2010</b> , 154, 297-306	20
40	A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients. <b>2017</b> , 9,	0
39	Genes Involved in Resistance to Carcinogenesis. <b>2000</b> , 27-42	
38	The potential role of immunosuppressive macrocyclic lactones. <b>2001</b> , 43-75	
37	Sirolimus. <b>2001</b> , 143-163	
36	Intestinal Drug Transport: Stereochemical Aspects. <b>2003</b> , 251-288	

- 35 Interaction of herbs with other medicines. **2003**, 171-186
- 34 Drug-Metabolizing Enzymes and P-Glycoprotein. **2004**, 43-67
- 33 Cyclosporin. **2005**, 221-236
- 32 Pharmacogenetics. **2006**, 161-176
- 31 Drug Interactions with Botanical Products. **2006**, 25-47
- 30 Drug-Metabolizing Enzymes. **2009**, 85-117
- 29 Drug Transporters. **2009**, 45-84 2
- 28 Immunoregulatory Drugs. **2009**, 909-927 1
- 27 Interplay of Drug Metabolizing Enzymes and ABC Transporter. *Methods and Principles in Medicinal Chemistry*, **2009**, 325-347 0.4
- 26 Peroral Toxicity.
- 25 Clinical Pharmacologic Principles and Immunosuppression. **2011**, 87-109
- 24 Optimization of Experimental Conditions for In vitro P-glycoprotein Assay Using LLC-GA5 Cells. *Journal of Pharmaceutical Investigation*, **2010**, 40, 363-366 6.3
- 23 Gender and pharmacokinetics\*. **2012**, 226-230
- 22 Changes in P-glycoprotein during Treatment with Anti-cancer Drug and its Influence on Pharmacokinetics and Pharmacological Effects. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2014**, 40, 193-207 0.1 1
- 21 Application of Genotyping and Gene-Expression on Personalized Immunosuppressive Therapy in Liver Transplant Patients. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2015**, 46, 43-49 0
- 20 Cardiovascular Catheterization, Electrophysiology, and Imaging Laboratory Procedures. **2015**, 352-397
- 19 Immunosenescence and Immunosuppressive Drugs in the Elderly. **2018**, 1-21
- 18 Immunosenescence and Immunosuppressive Drugs in the Elderly. **2019**, 2147-2167

17	Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> ,	4.5	3
16	Cyclosporin therapeutic drug monitoring--an established service revisited. <i>Clinical Biochemist Reviews</i> , <b>2003</b> , 24, 33-46	7.3	19
15	Tacrolimus interaction with clotrimazole: a concise case report and literature review. <i>P and T</i> , <b>2010</b> , 35, 568-9	1.4	7
14	Genetic polymorphisms of pharmacogenomic VIP variants in the lloba population of southwest China. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 13293-303	1.4	14
13	DrugDrug interactions and their implications on the pharmacokinetics of the drugs. <b>2022</b> , 291-322		
12	Intestinal Epithelium and Drug Transporters. <b>2022</b> , 39-64		
11	DIET/NUTRIENT INTERACTIONS WITH DRUG TRANSPORTERS. <b>2022</b> , 515-541		
10	Drug interactions. <b>2013</b> , 730-746.e2		
9	Drugs for the skinternist. <b>2013</b> , 408-423.e3		
8	Relevance of ABC Transporters in Drug Development. <i>Current Drug Metabolism</i> , <b>2022</b> , 23,	3.5	2
7	Novel insights in drug transporter sciences: the year 2021 in review. <i>Drug Metabolism Reviews</i> , 1-19	7	
6	COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.		0
5	Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients. <b>2022</b> , 14, 2441		2
4	Food effects on gastrointestinal physiology and drug absorption. <b>2022</b> , 100488		0
3	Evaluation and prediction of oral drug absorption and bioequivalence with food-druginteraction. <b>2023</b> , 50, 100502		0
2	Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. 14,		0
1	Simulated Microgravity Alters P-Glycoprotein Efflux Function and Expression via the Wnt/ECatenin Signaling Pathway in Rat Intestine and Brain. <b>2023</b> , 24, 5438		0